IT / EN

Pompe Disease (Glycogen Type II)

Pompe disease is a lysosomal glycogen storage disorder, inherited in an autosomal recessive manner, and caused by a deficiency of the enzyme acid alpha-glucosidase (GAA).

In the absence of this enzyme, glycogen progressively accumulates primarily within the lysosomes of skeletal and cardiac muscle. This buildup severely compromises both contractile function and cellular energy production.

Epidemiology and Treatment

Prevalence: The classic infantile-onset form affects approximately 1:40,000 live births, while the overall frequency (including late-onset forms) is estimated between 1:20,000 and 1:40,000.
Clinical Milestone: It is currently the only muscular glycogen storage disease for which an enzyme replacement therapy (ERT) is available.

The pathology is caused by biallelic molecular defects in the GAA gene (located on chromosome 17q25.3), which encodes the enzyme lysosomal acid alpha-glucosidase.

Inheritance and Variants

Inheritance Pattern: The condition is transmitted in an autosomal recessive manner.
Mutational Spectrum: Hundreds of pathogenic variants have been identified to date.
Genotype-Phenotype Correlation: While the correlation is partial, mutations that result in a complete loss of enzymatic activity (null alleles) are typically associated with the more severe infantile-onset forms.

Specific Alleles

A specific splicing variant that is relatively common in Caucasian populations (c.-32-13T>G) is strongly associated with the late-onset form (LOPD). This mutation allows for partial residual enzymatic activity, which accounts for the slower progression and later clinical manifestation of the disease.

The clinical presentation is broad and directly correlates with the level of residual enzymatic activity.

Classic Infantile-Onset Pompe Disease (IOPD)

Onset: Within the first year of life (typically $<6$ months).
Clinical Features: Severe hypotonia (“floppy infant syndrome”), hypertrophic cardiomyopathy with potential heart failure, progressive respiratory failure, and diminished or absent deep tendon reflexes.
Prognosis: Without treatment, survival beyond the first year of life is rare.

Juvenile Form

Onset: Between 1 and 20 years of age.
Clinical Features: Predominant skeletal muscle involvement with progressive weakness, delayed motor milestones, and potential respiratory involvement. Cardiomyopathy is typically absent or mild.

Adult-Onset Pompe Disease (LOPD)

Onset: After 20 years of age, frequently presenting in the third or fourth decade.
Clinical Features: Slowly progressive proximal muscle weakness, primarily with an axial and limb-girdle distribution.
Respiratory Alert: Diaphragmatic involvement may precede limb weakness, leading to respiratory insufficiency even in the absence of significant peripheral weakness.
Skeletal Involvement: Secondary development of scoliosis is common.
Laboratory Findings: Serum Creatine Kinase (CK) levels are elevated, though often less markedly than in other metabolic myopathies.

Clinical suspicion is based on the identification of progressive proximal muscle weakness, persistent hyperCKemia, respiratory insufficiency disproportionate to limb weakness, and, in infantile forms, hypertrophic cardiomyopathy. Newborn Screening (NBS) programs, now active in several countries, allow for pre-symptomatic identification.
- Muscle MRI: Reveals a characteristic pattern with early involvement of the paraspinal muscles, the gluteus maximus, and the thigh muscles (specifically the semitendinosus and biceps femoris), typically showing relative sparing of the rectus femoris.
- Enzymatic Activity (DBS): Measurement of enzyme activity via Dried Blood Spot (DBS) is the first-tier test; it is minimally invasive and highly sensitive. Confirmation is obtained by measuring enzymatic activity in lymphocytes or fibroblasts.
- Muscle Biopsy: Shows PAS-positive lysosomal vacuoles with positive staining for acid phosphatase. In late-onset forms (LOPD), these histological features may be less prominent or more focal.
- Molecular Diagnosis: Definitive confirmation is achieved through GAA gene sequencing. In cases where DBS shows reduced activity but the genotype is inconclusive (e.g., variants of uncertain significance), biochemical confirmation on tissue is decisive.
The “Centro Dino Ferrari” Protocol

The Centro Dino Ferrari provides a comprehensive diagnostic pathway for Pompe disease, integrating clinical, histological, molecular, and biochemical assessments:
- Glycogen quantification (dosage).
- Residual enzymatic activity assays on lymphocytes, primary cells, or muscle biopsy.
- Qualitative and quantitative analysis of GAA protein levels (Western Blot/ELISA).
- Advanced molecular techniques for complex variant interpretation.

Available therapies

Pompe disease is the only muscular glycogen storage disease for which an enzyme replacement therapy (ERT) is currently approved. There are now three approved ERTs, all administered via intravenous (IV) infusion every two weeks.

Approved Pharmacological Therapies

Alglucosidase alfa: The first available ERT (approved in 2006), which radically changed the prognosis of the infantile-onset form.
Avalglucosidase alfa: A second-generation formulation designed with enhanced muscle uptake, demonstrating greater efficacy in slowing the decline of respiratory and motor functions.
Cipaglucosidase alfa + Miglustat: The most recent therapeutic strategy. Miglustat acts as a pharmacological chaperone, stabilizing the enzyme in the bloodstream and improving its tissue distribution.

Treatment Efficacy and Monitoring

Early Intervention: ERT efficacy is maximized when treatment is initiated early, particularly in infantile forms identified through Newborn Screening (NBS).
Immunological Monitoring: The primary adverse effects include infusion-associated reactions (IARs) and the development of anti-drug antibodies (ADAs). Monitoring the immune response is an essential part of clinical follow-up.

Multidisciplinary Support

Respiratory and Physical Therapy: Specialized physiotherapy and non-invasive ventilation (NIV) are fundamental components of care for patients with respiratory insufficiency.
Cardiological Follow-up: Mandatory for infantile forms (IOPD) and strongly recommended for all other clinical presentations to monitor potential complications.

Research in progress

Innovative therapeutic approaches are currently under investigation to further improve long-term outcomes:

Gene Therapy: Clinical trials are exploring the use of AAV (Adeno-Associated Virus) vectors designed to target skeletal muscle and the diaphragm directly, aiming to restore endogenous enzyme production.
Progression Biomarkers: Ongoing research into reliable biomarkers is critical for monitoring disease progression and evaluating the real-time response to therapy.
Clinical Trials: The “Centro Dino Ferrari” actively participates in multicenter clinical trials for Pompe disease, including studies on next-generation therapies and novel enzymatic formulations.